NCT00499200View on ClinicalTrials.gov

Study Evaluating Safety, Tolerability, Pharmacokinetics and 5 HT1A Receptor Occupancy

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
Alzheimer's Disease
Interventions
DRUG

SRA-444

Trial Locations (1)

753 23

Uppsala

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00499200 - Study Evaluating Safety, Tolerability, Pharmacokinetics and 5 HT1A Receptor Occupancy | Biotech Hunter | Biotech Hunter